Skip to content
OpenCapital
Get started

Polaryx Therapeutics, Inc. PLYX Share-Based Payment - Unrecognized Cost of Nonvested Awards

Share-Based Payment - Unrecognized Cost of Nonvested Awards at other companies

Wintrust Financial logo
Wintrust FinancialWTFC
$47.7M+1.1%
Service Corporation International logo
Service Corporation InternationalSCI
$6.6M-5.7%
Otis Worldwide logo
Otis WorldwideOTIS
$125M-15.5%
International Paper logo
International PaperIP
$137M-8.7%
Valley National Bank logo
Valley National BankVLY
$69.5M+34.4%
APA Corporation logo
APA CorporationAPA
$6M—

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M—

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$115.64M—

Returns & leverage

See full
Return on equity-1,209.8%—
Current ratio3.5×—

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions.

The official record: Polaryx Therapeutics, Inc. ’s 10-K, filed March 24, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's share-based payment - unrecognized cost of nonvested awards.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's share-based payment - unrecognized cost of nonvested awards?
Polaryx Therapeutics, Inc. (PLYX) reported share-based payment - unrecognized cost of nonvested awards of $7.6M in Q4 2025.
What does share-based payment - unrecognized cost of nonvested awards mean?
This represents the total compensation expense for equity-based awards that has been granted but not yet recognized in the income statement because the vesting conditions have not been met. It serves as a forward-looking indicator of future non-cash compensation expenses. Investors use this to forecast the impact of stock-based compensation on future earnings.